Trial data from AstraZeneca on Aug. 20 raised the prospect of a new treatment to prevent Covid-19 beyond vaccines, giving hope in particular for people who respond poorly to immunization shots.
The National Institutes of Health (NIH) raised concern about the safety of AstraZeneca’s coronavirus vaccine as the U.S. Food and Drug Administration is weighing whether or not to resume testing in the United States following a global pause in the Phase III trial for safety reasons.
U.S. hospitals have turned down about a third of their allocated supplies of the Covid-19 drug remdesivir since July as need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed.
In a study published in Nature Medicine, scientists at Columbia University and Vanderbilt University describe how they were able to successfully restore badly damaged lungs in order to use them for lung transplants.